Summary
This mechanistic study elucidates the molecular basis of thrombotic complications in myeloproliferative neoplasms by demonstrating that JAK2V617F mutations and thrombopoietin signalling promote a previously undercharacterised intermediate-affinity state (E+H−) of the platelet integrin αIIbβ3. Using transgenic mouse models and patient samples alongside novel microfluidics and FRET-based flow cytometry assays, the authors show that this integrin priming state enhances platelet adhesiveness and contributes to increased venous thrombosis risk. The findings provide insights into the paradoxical thrombotic tendency observed clinically in MPN patients despite concurrent platelet dysfunction.
Regional applicability
This fundamental research on MPN-associated thrombosis mechanisms is relevant to UK clinical haematology and may inform stratification and management strategies for MPN patients at risk of thrombotic events. However, the study is laboratory-based and does not directly address prevention or treatment strategies applicable to UK clinical practice.
Key measures
Platelet adhesive behaviour under flow conditions, thrombus formation, αIIbβ3 integrin conformation state (bent low-affinity B+, extended high-affinity E+H+, and intermediate-affinity E+H− states), platelet rolling and stable adhesion, venous thrombosis in inferior vena cava stenosis and femoral vein electrolytic injury models
Outcomes reported
The study characterised how JAK2V617F mutations and thrombopoietin signalling promote an intermediate-affinity state (E+H−) of the platelet integrin αIIbβ3, using transgenic mouse models and patient samples with microfluidics and flow cytometry-based FRET assays. Findings linked E+H− αIIbβ3 priming to increased venous thrombosis risk in MPN patients.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.